Stock Detail
Videos
PolyPid (PYPD) Company Webcast
PolyPid Ltd. (NASDAQ: PYPD) is a late-stage biopharmaceutical company developing innovative therapies designed to improve surgical outcomes and reduce post-operative complications. The company's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology enables...
PolyPid (PYPD) Company Webcast
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. This company webcast was recorded during the Lytham Partners 2026 Investor Healthcare Summit.
PolyPid (PYPD) Fireside Chat
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. This fireside chat was recorded during the Lytham Partners Fall 2025 Investor Conference.
News
PolyPid Completes New Drug Application Submission to FDA for D-PLEX
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq:...
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initiated NDA Submission to the FDA for D-PLEX ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD)...